iMDx's GraftAssure Assay Validated in Lancet Study for Kidney Transplant Drug Management
Event summary
- iMDx's GraftAssure assay demonstrated efficacy in guiding treatment decisions for kidney transplant patients using felzartamab, a CD38-targeted therapy, as published in The Lancet Regional Health – Europe on July 23, 2026.
- The study showed that dd-cfDNA testing via GraftAssure can reduce drug usage by approximately two-thirds compared to unguided administration.
- iMDx received Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing from MolDX, a CMS program.
- GraftAssureDx, iMDx's FDA-reviewed kit for clinical use, aims to expand localized access to dd-cfDNA testing technology.
The big picture
The validation of iMDx's GraftAssure assay in managing kidney transplant rejection with felzartamab marks a significant step in personalized medicine for transplant patients. This study underscores the growing role of dd-cfDNA testing in guiding treatment decisions, potentially reducing drug usage and hospital visits. The strategic shift from centralized to localized testing could disrupt the current diagnostic landscape, making iMDx a key player in the evolving transplant diagnostics market.
What we're watching
- Regulatory Approval
- Whether the FDA will approve GraftAssureDx for clinical use, enabling broader adoption of dd-cfDNA testing in transplant centers.
- Market Expansion
- The pace at which iMDx can expand the use of GraftAssure beyond rejection detection to include active management of high-risk kidney transplant patients.
- Reimbursement Dynamics
- How Medicare reimbursement coverage will impact the commercial adoption of iMDx's GraftAssure assay portfolio.
Related topics